Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 145, w14100. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14100

[img]
Preview
Text
smw-2015-14100.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (872kB) | Preview

The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Pabst, Thomas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1424-7860

Publisher:

EMH Schweizerischer Ärzteverlag

Language:

English

Submitter:

Marianne Zahn

Date Deposited:

17 Mar 2016 14:51

Last Modified:

18 Mar 2016 10:02

Publisher DOI:

10.4414/smw.2015.14100

PubMed ID:

25999239

BORIS DOI:

10.7892/boris.77200

URI:

https://boris.unibe.ch/id/eprint/77200

Actions (login required)

Edit item Edit item
Provide Feedback